177Lu-NeoBOMB1

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug Name177Lu-NeoBOMB1
Drug Alias NameLutetium-177 NeoBOMB1[177Lu]Lu-NeoB[177Lu]NeoBOMB-1[177Lu]-NeoB177LuNeoBOMB1 +[7] 
ClassificationDiagnostic agent (In vivo)Radiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates +[5] 
Mechanisms of ActionGastrin releasing peptide receptor antagonists
TargetsGastrin releasing peptide receptor
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[15] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesAdvanced Accelerator Applications SaNovartis Pharma AgChina Novartis Institutes For Biomedical Research Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A